{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:51Z","timestamp":1760239851470,"version":"build-2065373602"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.hoc.2020.03.002","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T08:07:53Z","timestamp":1588666073000},"page":"743-756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Collin K.","family":"Chin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"Surveillance, epidemiology, and end results (SEER) program","key":"10.1016\/j.hoc.2020.03.002_bib1"},{"key":"10.1016\/j.hoc.2020.03.002_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/bjh.13316","article-title":"A\u00a0population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait","volume":"169","author":"El-Galaly","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.03.002_bib3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/leu.2014.251","article-title":"Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study","volume":"29","author":"Junlen","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.03.002_bib4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.03.002_bib5","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib6","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib8","doi-asserted-by":"crossref","unstructured":"Li X, Kositsky R, Reddy A, et\u00a0al: Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. Blood 2019;134(Supplement_1):19.","DOI":"10.1182\/blood-2019-130255"},{"key":"10.1016\/j.hoc.2020.03.002_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.002_bib10","doi-asserted-by":"crossref","unstructured":"Vallee A, Shourian M, Johnson N, et\u00a0al. Evaluation of T-Cell Compartment By Complex Multiparameter Flow Cytometry Reveals Distinct Patterns of T-Cell Exhaustion in DLBCL, FL and HL Patients. Blood 2019;134(Supplement_1):2806.","DOI":"10.1182\/blood-2019-130647"},{"key":"10.1016\/j.hoc.2020.03.002_bib11","doi-asserted-by":"crossref","unstructured":"Haebe S, Shree T, Sathe A, et\u00a0al. Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing. Blood 2019;134(Supplement_1):297.","DOI":"10.1182\/blood-2019-129445"},{"key":"10.1016\/j.hoc.2020.03.002_bib12","doi-asserted-by":"crossref","unstructured":"Nath K, Law SC, Sabdia MB, et\u00a0al. Intra-Tumoral CD8+ T-Cells in Follicular Lymphoma Contain Large Clonal Expansions That Are Amenable to Dual-Checkpoint Blockade. Blood 2019;134(Supplement_1):2793.","DOI":"10.1182\/blood-2019-130050"},{"key":"10.1016\/j.hoc.2020.03.002_bib13","doi-asserted-by":"crossref","unstructured":"Mondello P, Fama A, Larson M, et\u00a0al. Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood 2019;134(Supplement_1):121.","DOI":"10.1182\/blood-2019-126233"},{"key":"10.1016\/j.hoc.2020.03.002_bib14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2020.03.002_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.hoc.2020.03.002_bib16","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T\u00a0cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2020.03.002_bib17","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-11-0993","article-title":"IL-18 induces PD-1-dependent immunosuppression in cancer","volume":"71","author":"Terme","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2020.03.002_bib18","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1200\/JCO.2017.35.15_suppl.7519","article-title":"Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: interim results of an on open-label, phase II study","volume":"35","author":"Nastoupil","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib19","doi-asserted-by":"crossref","unstructured":"Barraclough A, Chong G, Gilbertson M, et\u00a0al. Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the \u20181st FLOR\u2019 Study. Blood 2019;134 (Supplement_1):1523.","DOI":"10.1182\/blood-2019-123908"},{"key":"10.1016\/j.hoc.2020.03.002_bib20","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib21","doi-asserted-by":"crossref","unstructured":"Armand P, Zinzani PL, Palcza J, et\u00a0al. Phase 1-2 Study of Pembrolizumab Combined with the Anti\u2013LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies. Blood 2019;134(Supplement_1):1548.","DOI":"10.1182\/blood-2019-127474"},{"key":"10.1016\/j.hoc.2020.03.002_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2020.03.002_bib23","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2020.03.002_bib24","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2020.03.002_bib25","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.03.002_bib26","doi-asserted-by":"crossref","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2020.03.002_bib27","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2020.03.002_bib28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hoc.2020.03.002_bib29","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1586\/14737140.7.10.1439","article-title":"Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents","volume":"7","author":"Bishton","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.hoc.2020.03.002_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminoncol.2018.07.005","article-title":"New concepts in follicular lymphoma biology: from BCL2 to epigenetic regulators and non-coding RNAs","volume":"45","author":"Devan","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib31","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.002_bib32","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A\u00a0multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.03.002_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A\u00a0phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"100","author":"Chen","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.03.002_bib35","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.ejca.2013.05.009","article-title":"Pharmacokinetic\/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454\/PCI-24781) in phase I","volume":"49","author":"Fouliard","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hoc.2020.03.002_bib36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2016.154377","article-title":"Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study","volume":"102","author":"Ribrag","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.03.002_bib37","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A\u00a0phase I\/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed\/refractory lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2020.03.002_bib38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A\u00a0phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.03.002_bib39","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"Bodor","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.002_bib40","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.hoc.2020.03.002_bib41","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Tilly H, Chaidos A, et\u00a0al. Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. Blood 2019;134 (Supplement_1):123.","DOI":"10.1182\/blood-2019-128096"},{"key":"10.1016\/j.hoc.2020.03.002_bib42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points","volume":"116","author":"Danial","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2020.03.002_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.molcel.2011.10.001","article-title":"A\u00a0unified model of mammalian BCL-2 protein family interactions at the mitochondria","volume":"44","author":"Llambi","year":"2011","journal-title":"Mol Cell"},{"key":"10.1016\/j.hoc.2020.03.002_bib44","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib45","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib46","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/349254a0","article-title":"Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18)","volume":"349","author":"McDonnell","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2020.03.002_bib47","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1200\/JCO.2013.52.8190","article-title":"t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma","volume":"32","author":"Roulland","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib48","doi-asserted-by":"crossref","unstructured":"Gibbs D, Van Besien H, Regan S, et\u00a0al. Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes. Blood 2019;134 (Supplement_1):304","DOI":"10.1182\/blood-2019-126790"},{"issue":"9","key":"10.1016\/j.hoc.2020.03.002_bib49","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study","volume":"29","author":"de Vos","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib50","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.346","article-title":"Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells","volume":"23","author":"Gobessi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2020.03.002_bib51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15552","article-title":"An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma","volume":"184","author":"Andorsky","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.03.002_bib52","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood-2014-06-582650","article-title":"Activating STAT6 mutations in follicular lymphoma","volume":"125","author":"Yildiz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.002_bib53","doi-asserted-by":"crossref","unstructured":"Smith S, Munoz J, Stevens D, et\u00a0al. Rapid and Durable Responses with the SYK\/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed\/Refractory Follicular Lymphoma\u2014Alone or in Combination with Rituximab. Blood 2019;134(Supplement_1):3981.","DOI":"10.1182\/blood-2019-124231"},{"key":"10.1016\/j.hoc.2020.03.002_bib54","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib56","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2020.03.002_bib57","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/jco.2015.33.15_suppl.8503","article-title":"Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed\/refractory (RR) follicular lymphoma (FL): durable responses at lower dose level","volume":"33","author":"Advani","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib58","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2018.36.15_suppl.7507","article-title":"Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed\/refractory (r\/r) FL and DLBCL","volume":"36","author":"Sehn","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib59","doi-asserted-by":"crossref","unstructured":"Diefenbach C, Kahl B, Banerjee L, et\u00a0al. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed\/refractory follicular lymphoma: primary analysis of the full efficacy population in a phase Ib\/II trial. Blood 2019;134(Supplement_1):126.","DOI":"10.1182\/blood-2019-123669"},{"key":"10.1016\/j.hoc.2020.03.002_bib60","doi-asserted-by":"crossref","unstructured":"Fowler N, Nastoupil L, Chin CK, et\u00a0al. A Phase I\/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma. Blood 2019;134(Supplement_1):348.","DOI":"10.1182\/blood-2019-131045"},{"key":"10.1016\/j.hoc.2020.03.002_bib61","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2020.03.002_bib62","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib63","doi-asserted-by":"crossref","unstructured":"Moustafa MA, Parrando R, Wiseman G, et\u00a0al. Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience. Blood 2019;134(Supplement_1):2809.","DOI":"10.1182\/blood-2019-129391"},{"key":"10.1016\/j.hoc.2020.03.002_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.hoc.2020.03.002_bib65","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T\u00a0cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.hoc.2020.03.002_bib66","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bartlett NL, Assouline S, et\u00a0al. Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Blood 2019;134 (Supplement_1):6.","DOI":"10.1182\/blood-2019-123742"},{"key":"10.1016\/j.hoc.2020.03.002_bib67","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Carlo-Stella C, Offner F, et\u00a0al. Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. Blood 2019;134(Supplement_1):1584.","DOI":"10.1182\/blood-2019-123949"},{"key":"10.1016\/j.hoc.2020.03.002_bib68","doi-asserted-by":"crossref","unstructured":"Baliga R, Li J, Manlusoc M, et\u00a0al. High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release. Blood 2019;134 (Supplement_1):1574.","DOI":"10.1182\/blood-2019-131650"},{"key":"10.1016\/j.hoc.2020.03.002_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.74_2629","article-title":"Efficacy and safety of obinutuzumab\u00a0+ lenalidomide\u00a0+ atezolizumab in patients with relapsed or refractory follicular lymphoma: primary analysis of a phase 1B\/2 trial","volume":"37","author":"Morschhauser","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib70","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood.V128.22.617.617","article-title":"Phase 2 study of venetoclax plus rituximab or randomized ven plus bendamustine+rituximab (BR) versus BR in patients with relapsed\/refractory follicular lymphoma: interim data","volume":"128","author":"Zinzani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.03.002_bib71","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1200\/JCO.2019.37.15_suppl.7518","article-title":"Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL)","volume":"37","author":"Bartlett","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.03.002_bib72","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hon.59_2629","article-title":"CD20-TCB (RG6026), a novel \u201c2:1\u201d format T-cell-engaging bispecific antibody, induces complete remissions in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"37","author":"Dickinson","year":"2019","journal-title":"Hematol Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:11Z","timestamp":1760184851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0889858820300381"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.03.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}